Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.70 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | AGXT | P21549 | 1/20 | 0.61 |
| ▸ | CFD | P00746 | 4/20 | 0.56 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | PNMT | P11086 | 1/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | F11 | P03951 | 1/20 | 0.50 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.50 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400616 | 1.00 | TAAR1 (0.70) | TAAR1LOXL2AGXTCFDAOC3 | |
| Hydrochloric Acid SCHEMBL29793666 | 0.98 | TAAR1 (0.67) | TAAR1LOXL2AGXTCFDAOC3 | |
| Hydrochloric Acid SCHEMBL1237399 | 0.98 | TAAR1 (0.67) | TAAR1LOXL2AGXTCFDAOC3 | |
| Bromide SCHEMBL1856525 | 0.98 | TAAR1 (0.67) | TAAR1LOXL2AGXTCFDAOC3 | |
| SCHEMBL28247640 | 0.98 | TAAR1 (0.74) | TAAR1LOXL2AGXTCFDAOC3 | |
| SCHEMBL27799749 | 0.98 | TAAR1 (0.67) | TAAR1LOXL2AGXTCFDAOC3 | |
| SCHEMBL3791745 | 0.93 | LOXL2 (0.60) | TAAR1LOXL2AGXTCFDHRH3 | |
| SCHEMBL3794460 | 0.91 | TAAR1 (0.70) | TAAR1LOXL2AGXTCFDHRH3 | |
| Benzylamine SCHEMBL11416949 | 0.90 | LOXL2 (0.74) | TAAR1LOXL2AGXTCFDAOC3 | |
| Biphenyl SCHEMBL27410798 | 0.90 | TAAR1 (0.84) | TAAR1LOXL2AGXTHRH3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 596 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114695807-A | Composite material, preparation method thereof and light emitting diode | TCL科技集团股份有限公司 | 2022-07-01 | — | — | CN | claimed |
| US-8614201-B2 | Heterocyclic amides as modulators of TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-24 | — | — | US | claimed |
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-1812004-B1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2011-06-22 | — | — | EP | claimed |
| WO-2010141805-A1 | HETEROCYCLIC AMIDES AS MODULATORS OF TRPA1 | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1610779-B1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| EP-1610779-A1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-01-04 | — | — | EP | claimed |
| WO-2004099127-A1 | NOVEL COMPOUNDS AS KINASE INHIBITORS | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| WO-2004093872-A1 | 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | TANABE SEIYAKI CO., LTD. (JP) | 2004-05-20 | — | — | US | claimed |
| CN-1466573-A | 5-phenylbenzylamine compounds, process for their production and intermediates for their synthesis | 田边制药株式会社 | 2004-01-07 | — | — | CN | claimed |
| EP-1323713-A1 | 5-PHENYLBENZYLAMINE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND INTERMEDIATES FOR THEIR SYNTHESIS | TANABE SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| WO-1999031124-A1 | CHOLIC ACID-BASED SCAFFOLDS FOR MULTIDIMENSIONAL MOLECULAR PRESENTATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 1999-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097548-A1 | 5-Phenylbenzylamine compounds, process for their production and intermediates for their synthesis | CYP1B1, MAOB, HTR1B | TAAR1 418/4885LOXL2 4752/4885AGXT 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.